Better Stock Today Challenge: Seadrill vs. Isis Pharmaceuticals

In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner.

Today it's the Semi-Final stage, and Seadrill takes on Isis Pharmaceuticals in our search for the better stock.

Bracket showing companies that advanced from the group stages

Joel South, energy analyst at The Motley Fool, thinks Seadrill (NYSE: SDRL) is more than worthy of your consideration today. Successful investors have been building significant wealth for years by finding solid, high dividend paying stocks. Seadrill sports an industry leading 10% yield and with solid contract coverage and a fleet of new drilling rigs, investors can count on Seadrill to be among the best offshore drillers in the world.

David Williamson, Motley Fool health care analyst, thinks Isis Pharmaceuticals (NASDAQ: ISIS  ) should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.

Do you know this energy tax "loophole"?
You already know record oil and natural gas production is changing the lives of millions of Americans. But what you probably haven't heard is that the IRS is encouraging investors to support our growing energy renaissance, offering you a tax loophole to invest in some of America's greatest energy companies. Take advantage of this profitable opportunity by grabbing your brand-new special report, "The IRS Is Daring You to Make This Investment Now!," and you'll learn about the simple strategy to take advantage of a little-known IRS rule. Don't miss out on advice that could help you cut taxes for decades to come. Click here to learn more.

Vote here to determine the winner of this match and sound off in the comments box below. Check back to Fool.com to see who advances in the final.


Read/Post Comments (5) | Recommend This Article (12)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 24, 2014, at 11:29 PM, tbash789 wrote:

    Again I have to write and note that Seadrill is a worthy investment just like LINN Energy was, but this does not compare in any way to ISIS if someone is really interested in wealth building. A ten percent dividend might be right for some investors, but if you look at what happened to VRTX today with an over $24 point gain you can see the potential with holding the right biotech.

    ISIS is the right biotech. They have at least four, probably six medications at this time that could be billion dollar sellers by the year 2018.

    Their GCGR blocker for DM Type 2 IMO could be the biggest medication to treat DM Type 2 in over seven years. Unlike the GLP-1 agonists which are in and of themselves good drugs, this drug works better, with less side-effects. It goes after the glucagon receptor and really blocks it almost completely. It also acts as a GLP-1 agonist as well. This drug lowered HgbA1c more than any other drug I've ever seen and it did it in 13 weeks. What that means is that it probably will lower your HgbA1c even more over time. It didn't cause the side effects of nausea, and vomiting that you see with the GLP-1 agonists. If priced right this drug could completely leap-frog the most important drug class to come out in over seven years. Some people estimate that this drug could do $5 to $7 billion in sales. The beauty of this drug is that it helps patients with DM who are insulin resistant who have continued increases in their insulin to almost no avail in controlling their DM. You lower their insulin requirements AND get lower serum glucose at the same time. Talked to the leading DM expert in my state who is truly excited about this drug.

    Their TTR-amyloidosis drug for polyneuropathy is an orphan drug that is looking to have first mover advantage over the competition. It will probably IMO maintain that advantage based on ease of administration, cost, and competitive strength. This could also be a billion dollar drug.

    ISIS Factor XI inhibitor could also be a billion dollar drug. In their proof of concept testing of the drug in assessing its ability to stop deep vein thrombosis(blood clots) post total knee joint replacement, it out performed the standard of care by lowering your risk of a DVT by seven fold, WITHOUT ANY BLEEDS. Moreover this drug may have over four or five indications.

    ISIS ApoCIII inhibitor has been in the news for potential to lower cardiovascular risk by lowering your triglycerides and raising your HDL. A New England Journal Medicine( the bible of up to date medicine and medical trends) ran an article on the possible importance of ApoCIII as treatment and biomarker in lowering your CV risk. A truly potentially valuable medicine with at least three indications.

    I could go on and on as ISIS has 32 drugs in their pipeline. Piper Jafferies had noted that they may have the most valuable biotech pipeline out there. I do know that by the end of the year this stock will have returned over a decade's rate of return compared to the other competitor in this competition. t

  • Report this Comment On June 25, 2014, at 6:38 PM, MostlyFools wrote:

    Just to clarify David Williamson's Isis video clip, Kynamro, not Juxtapid, is Isis' first marketed systemic antisense drug. Its FDA approval validated Isis' antisense platfrorm. Juxtapid is a competitor's drug for the same indication.

  • Report this Comment On June 27, 2014, at 7:59 PM, GW1000 wrote:

    My answer is to buy both! SDRL is a solid, high-yielder and ISIS is a more speculative biotech company with multibagger potential.

  • Report this Comment On June 27, 2014, at 8:05 PM, GW1000 wrote:

    I just noticed that Linn Energy got picked over FB. Not sure about that one. FB rocks

    !

  • Report this Comment On August 05, 2014, at 11:00 AM, MayTepper wrote:

    We Expect ISIS Shares To Outperform The Market, Says Cowen http://bit.ly/1pAIVcv

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3006229, ~/Articles/ArticleHandler.aspx, 10/21/2014 2:15:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement